
Opinion|Videos|December 16, 2024
Demographics and Baseline Characteristics Across Spesolimab Dose Groups
Key Takeaways
Panelists discuss how the Effisayil 2 trial included diverse patient demographics across different spesolimab dose groups, with baseline characteristics such as age, disease severity, and history of GPP flares influencing the treatment outcomes and safety data.
Advertisement
Episodes in this series

Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Oruka Reports Positive Interim Phase 1 Data for ORKA-002, Advances ORKA-001
2
Recludix Pharma’s REX-8756 for Type 2 Inflammatory Diseases Enters First Human Trials
3
Alpha Tau Submits First PMA Module to FDA for Novel cSCC Treatment, Alpha DaRT
4
French Early Access Data on Dupilumab in Pediatric Atopic Dermatitis
5

















